Compositions And Methods For Heparan Sulfate As A Biomarker For Transplant Rejection
AssigneeDuke University
InventorsTodd V. Brennan, Yiping Yang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of identifying transplant rejection through the use of heparan sulfate as a biomarker. Method also comprise treating and/or preventing transplant rejection in a subject comprising administering to the subject a heparan sulfate inhibitor, thereby treating and/or preventing the development of immune-mediated injury following transplantation.
Claims25
-29. (canceled)
A method of treating or ameliorating an injurious condition associated with elevated heparan sulfate comprising administering an inhibitor that decreases serum heparan sulfate to a therapeutically effective level, to a subject that was the recipient of a transplanted organ, tissue, or cells.
A method of preventing an injurious condition associated with elevated heparan sulfate comprising administering an inhibitor that decreases serum heparan sulfate to a therapeutically effective level, to a subject that was the recipient of a transplanted organ, tissue, or cells.
A method of diagnosing an injurious condition that is associated with elevated heparan sulfate in a subject that was the recipient of a transplanted organ, tissue, or cells, by collecting a biological sample from the subject and determining the serum concentration of heparan sulfate, where the concentration of heparan sulfate directly correlates with the severity of the heparan sulfate-mediated immune injury.
A composition comprising an inhibitor that decreases serum heparan sulfate to a therapeutically effective level in a transplant recipient subject, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.